Structure Therapeutics' Oral Obesity Drug Aleniglipron Shows Up To 16.2% Weight Loss in Phase 2B, Phase 3 to Start Q3
GPCR has more than doubled off its 52-week low of $15.8.
Summary
Structure Therapeutics' oral obesity drug, aleniglipron, demonstrated up to 16.2% weight loss beyond 36 weeks in its Phase 2b trial. This update provides specific, strong efficacy data following the initial positive mid-stage results announced in March and referenced in the Q1 10-Q. The drug also showed favorable tolerability with a 10.4% discontinuation rate, which is crucial for patient compliance in long-term treatments. The company plans to initiate the Phase 3 program for aleniglipron in Q3 2026.
At the time of this announcement, GPCR was trading at $38.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $15.80 to $94.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.